$ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Healthcare
Sector
Biotechnology
Industry
Matthew Gline
CEO
908
Employees
$27.80
Current Price
$19.67B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $6,848,573.48 | 241,861 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $6,848,573.48 | 241,861 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 22 | $201,146,591.63 | 7,458,654 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 25 | $234,433,092.10 | 8,989,522 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | Venker Eric President & Immunovant CEO | Sale | 200,000 | $28.24 | $5,648,000.00 | View Details |
| Mar 16, 2026 | Epperly Melissa B, Director | Sale | 41,861 | $28.68 | $1,200,573.48 | View Details |
| Feb 20, 2026 | Torti Frank President and Vant Chair | Sale | 1,012,610 | $27.15 | $27,492,361.50 | View Details |
| Feb 23, 2026 | Torti Frank President and Vant Chair | Sale | 587,390 | $27.51 | $16,159,098.90 | View Details |
| Feb 19, 2026 | Torti Frank President and Vant Chair | Sale | 1,400,000 | $27.42 | $38,388,000.00 | View Details |
| Feb 13, 2026 | Venker Eric President & Immunovant CEO | Sale | 200,000 | $26.49 | $5,298,000.00 | View Details |
| Feb 12, 2026 | MANCHESTER KEITH S Director | Sale | 275,000 | $26.76 | $7,359,000.00 | View Details |
| Feb 13, 2026 | MANCHESTER KEITH S Director | Sale | 150,784 | $26.49 | $3,994,268.16 | View Details |
| Feb 12, 2026 | MANCHESTER KEITH S Director | Sale | 150,000 | $26.72 | $4,008,000.00 | View Details |
| Feb 11, 2026 | MANCHESTER KEITH S Director | Sale | 425,000 | $26.67 | $11,334,750.00 | View Details |
| Feb 13, 2026 | MANCHESTER KEITH S Director | Sale | 225,000 | $26.50 | $5,962,500.00 | View Details |
| Feb 13, 2026 | Gold Daniel Allen Director | Sale | 150,784 | $26.49 | $3,994,268.16 | View Details |
| Feb 12, 2026 | Gold Daniel Allen Director | Sale | 275,000 | $26.76 | $7,359,000.00 | View Details |
| Feb 11, 2026 | Gold Daniel Allen Director | Sale | 425,000 | $26.67 | $11,334,750.00 | View Details |
| Feb 13, 2026 | Gold Daniel Allen Director | Sale | 225,000 | $26.50 | $5,962,500.00 | View Details |
| Feb 12, 2026 | Gold Daniel Allen Director | Sale | 150,000 | $26.72 | $4,008,000.00 | View Details |
| Feb 12, 2026 | QVT Financial LP Director by Deputization | Sale | 150,000 | $26.72 | $4,008,000.00 | View Details |
| Feb 12, 2026 | QVT Financial LP Director by Deputization | Sale | 275,000 | $26.76 | $7,359,000.00 | View Details |
| Feb 13, 2026 | QVT Financial LP Director by Deputization | Sale | 225,000 | $26.50 | $5,962,500.00 | View Details |
| Feb 11, 2026 | QVT Financial LP Director by Deputization | Sale | 425,000 | $26.67 | $11,334,750.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history